BioLineRx Ltd. American Depositary Shares (BLRX)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for understandable businesses with durable advantages and honest earning power. BioLineRx is a clinical-stage biopharmaceutical company with about 20 employees, developing GLIX1 and APHEXDA (motixafortide) for oncology and rare diseases. That is speculative medicine, and I see no durable moat I can underwrite. In the second quarter of 2026, revenue was only $294,000 and net income was -$3.0 million, a negative margin of -1,029.25%. Trailing free cash flow was -$10.8 million; against a $10.5 million market cap at the 2026-10-13 close, FairStock calculates an FCF yield of -103.1%. FairStock also shows ROE of -55.27%, ROCE of -19.82%, Piotroski F-Score of 0/9, and Altman Z-Score of -16.84. Those are distress signals, not evidence of earning power. On the asset side, the $2.17 close is near the low end of the 52-week range of $2.11-$4.07, and FairStock's P/B calculation is 0.72. A low price-to-book can attract a Graham investor, but in biotech, book value may be consumed by cash burn. With no meaningful earnings, no dividend, and a Lynch category of none because there are zero years of filed results and three are needed, this looks like a pipeline option, not a margin-of-safety bargain. I would need commercial revenue or clearer financing before treating the low price as value.

In plain English: BioLineRx develops experimental medicines for cancer and rare diseases. It is very small, brings in almost no revenue, and loses money each quarter. The stock price is low compared with its accounting book value, but because the company burns cash, it is not clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer